Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)

Inclusion Criteria: * Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial. * Male Chinese patient with severe congenital haemophilia A with a FVIII activity below 1% according to medical records. * Aged greater than or equal to 12 years at the time of signing informed consent. * History of at least 150 exposure days (EDs) to other FVIII products. * The patient and/or caregiver is capable of assessing a bleeding episode, keeping a diary, performing home treatment of bleeding episodes and otherwise following the trial procedures at the discretion of the investigator. Exclusion Criteria: * Known or suspected hypersensitivity to trial product or related products. * Previous participation in this trial. Participation is defined as signed informed consent. * Participation in any clinical trial of an approved or non-approved investigational medicinal product within 5 half-lives or 30 days from screening, whichever is longer. * Known history of FVIII inhibitors based on existing medical records, laboratory report reviews and patient and/or caregiver interviews. * Current FVIII inhibitors greater than or equal to 0.6 BU. * Congenital or acquired coagulation disorder other than haemophilia According to medical records. * HIV positive, defined by medical records, with CD4+ count less than or equal 200/L and a viral load greater …